Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms

Marito Araki1, Norio Komatsu2

  • 1Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Cancer Science
|July 26, 2017
PubMed

Insights

Mutations in the calreticulin (CALR) gene drive myeloproliferative neoplasms (MPN) by constitutively activating the thrombopoietin (TPO) receptor, MPL. This discovery reveals a new mechanism of cytokine receptor activation in cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Hematology

Background:

  • Cytokine-receptor signaling pathway deregulation is crucial in tumorigenesis.
  • Alterations in signaling pathway genes often cause deregulation.
  • Calreticulin (CALR) gene mutations were identified in Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) in late 2013.

Purpose of the Study:

  • To review the role of CALR mutations in oncogenic transformations in MPN.
  • To elucidate the molecular mechanism of CALR-mediated MPL activation.
  • To understand how mutant CALR induces cellular transformation.

Main Methods:

  • Review of existing literature on CALR mutations and MPN.
  • Analysis of the structural and functional consequences of CALR mutations.
  • Investigation of the interaction between mutant CALR and the TPO receptor (MPL).

Main Results:

  • All identified CALR mutations cause a +1 frameshift in exon 9, leading to a common mutant-specific C-terminus sequence.
  • Mutant CALR constitutively activates MPL independently of TPO, inducing cellular transformation.
  • Mutant CALR preferentially interacts with MPL via a conformational change, enabling N-domain binding.

Conclusions:

  • Mutant CALR activates the MPL receptor through a novel mechanism involving its unique C-terminus.
  • This aberrant activation of MPL by mutant CALR is a key driver of oncogenesis in a subset of MPN patients.
  • The findings highlight a new molecular pathway in cytokine receptor-driven cancers.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K